Skip to main content
SpringerLink
Log in

Polyneuropathie bei Patienten mit onkologischen Erkrankungen

  • Chapter
  • First Online:
Onkologische Rehabilitation

  • 2121 Accesses

Zusammenfassung

Die Polyneuropathie bei Patientinnen und Patienten mit onkologischen Erkrankungen kann als paraneoplastisches Syndrom sowie infolge einer Tumorbehandlung auftreten.

Die Untersuchungen im Rahmen der Diagnostik der Polyneuropathie bei Patientinnen und Patienten mit einer onkologischen Erkrankung bestehen aus Anamnese, klinischer Untersuchung (inkl. neurologischem Status), Laboruntersuchungen, elektrophysiologischer Untersuchung und Quantitative Sensory Testing. Fakultative Untersuchungen (je nach Differenzialdiagnose) sind die Lumbalpunktion, die Biopsie (Muskel-, Nerv- oder Hautbiopsie) und genetische Untersuchungen.

Die Therapie der Polyneuropathie bei Patientinnen und Patienten mit onkologischen Erkrankungen erfolgt interdisziplinär und multiprofessionell und besteht aus einer multimodalen Therapie. Hier ist die Kombination aus medikamentöser Therapie und physikalischen Therapien zu nennen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Abraham A, Alabdali M, Alsulaiman A (2017) The sensitivity and specificity of the neurological examination in polyneuropathy patients with clinical and electrophysiological correlations. PLoS One 12(3):e0171597

    PubMed  PubMed Central  Google Scholar 

  • Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113–3120

    PubMed  Google Scholar 

  • Antoine PJC, Camdessanché JP (2017) Paraneoplastic neuropathies. Curr Opin Neurol 30(5):513–520

    CAS  PubMed  Google Scholar 

  • Argyriou AA, Cavaletti G, Briani C (2013) Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119:438–444

    CAS  PubMed  Google Scholar 

  • Azhary H, Farooq MU, Bhanushali M, Majid A, Kassab MY (2010) Peripheral neuropathy: differential diagnosis and management. Am Fam Physician 81(7):887–892

    PubMed  Google Scholar 

  • Bruna J, Udina E, Ale A (2010) Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 223(2):599–608

    CAS  PubMed  Google Scholar 

  • Cavaletti G, Tredici G (2009) Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology 30:312–319

    PubMed  Google Scholar 

  • Cavaletti G, Cavalletti E, Montaguti P, Oggioni N, De Negri O, Tredici G (1997) Effect on the peripheral nervous system of the shortterm intravenous administration of paclitaxel in the rat. Neurotoxicology 18:137–145

    CAS  PubMed  Google Scholar 

  • Chu SH, Lee YJ, Lee ES, Geng Y, Wang XS, Cleeland CS (2015) Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. Support Care Cancer 23(2):513–524

    PubMed  Google Scholar 

  • Cocito D, Romagnolo A, Rosso M, Peci E, Lopiano L, Merola A (2015) CIDP-like neuropathies in graft versus host disease. J Peripher Nerv Syst 20(1):1–6

    PubMed  Google Scholar 

  • Crevenna R (2017) Kompendium Physikalische Medizin und Rehabilitation. Diagnostische und therapeutische Konzepte. Springer, Berlin/Heidelberg

    Google Scholar 

  • Crevenna R, Ashbury FD (2018) Physical interventions for patients suffering from chemotherapy-induced polyneuropathy. Support Care Cancer 26(4):1017–1018

    PubMed  Google Scholar 

  • De Wit R, Roberts JT, Wilkinson PM et al (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19:1629–1640

    PubMed  Google Scholar 

  • El-Kareh AW, Labes RE, Secomb TW (2008) Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs. AAPS J 10:15–34

    CAS  PubMed  PubMed Central  Google Scholar 

  • EORTC (1995) Quality of life group. Version 3.0. http://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf. Zugegriffen am 29.11.2018

  • Fehmi J, Scherer SS, Willison HJ, Rinaldi S (2018) Nodes, paranodes and neuropathies. J Neurol Neurosurg Psychiatry 89(1):61–71

    PubMed  Google Scholar 

  • Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP (2011) Validity of four pain intensity rating scales. Pain 152:2399–2404

    Google Scholar 

  • Freynhagen R, Baron R, Gockel U, Tölle TR (2006) painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22(10):1911–1920

    PubMed  Google Scholar 

  • Gertz MA (2014) Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol 89(12):1132–1140

    PubMed  Google Scholar 

  • Gill JS, Windebank AJ (1998) Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101:2842–2850

    CAS  PubMed  PubMed Central  Google Scholar 

  • Grisold W, Grisold A, Löscher WN (2016) Neuromuscular complications in cancer. J Neurol Sci 367:184–202

    CAS  PubMed  Google Scholar 

  • Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E (2001) A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85:2293–2297

    CAS  PubMed  Google Scholar 

  • Joseph EK, Chen X, Bogen O, Levine JD (2008) Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 9:463–472

    CAS  PubMed  Google Scholar 

  • Khan F, Amatya B (2012) Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review. Eur J Phys Rehabil Med 48(3):507–522

    CAS  PubMed  Google Scholar 

  • Klinke R, Silbernagel S (1996) Lehrbuch der Physiologie, 2. Aufl. Georg Thieme, Stuttgart/New York

    Google Scholar 

  • Koeppen S (2007) Management der therapiebedingten Neurotoxizität. Taube Stellen, kribbelnde Finger – Nervenschäden gezielt vermeiden. Im Focus Onkologie 11:64–70

    Google Scholar 

  • Krishnan AV, Goldstein D, Friedlander M, Kiernan MC (2005) Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32:51–60

    CAS  PubMed  Google Scholar 

  • Lauria G, Hsieh ST, Johansson O et al (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 17:903–912

    CAS  PubMed  Google Scholar 

  • Leitlinienprogramm Onkologie (2017) Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF. Supportive Therapie bei onkologischen PatientInnen– Langversion. http://www.awmf.org/uploads/tx_szleitlinien/032-054OLl_S3_Supportiv_2017-05.pdf. Zugegriffen am 29.11.2018

  • Manna A, Sarkar SK, Khanra LK (2015) PA1 – An internal audit into the adequacy of pain assessment in a hospice setting. BMJ Support Palliat Care 5(Suppl 1):A19–A20

    Google Scholar 

  • Mauermann ML (2018) The peripheral neuropathies of POEMS syndrome and castleman disease. Hematol Oncol Clin North Am 32(1):153–163

    PubMed  Google Scholar 

  • Mendell J, Kissel J, Cornblath D (2001) Diagnosis and management of peripheral nerve disorders. Oxford University Press, Oxford

    Google Scholar 

  • Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24:4507–4514

    CAS  PubMed  Google Scholar 

  • Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M (2010) Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 95:311–319

    CAS  PubMed  PubMed Central  Google Scholar 

  • Morawska M, Grzasko N, Kostyra M, Wojciechowicz J, Hus M (2015) Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol 33(4):113–119

    CAS  PubMed  Google Scholar 

  • Müller K, Meineke V (2011) Radiation induced mast cell mediators differentially modulate chemokine release from dermal fibroblasts. J Dermatol Sci 61(3):199–205

    PubMed  Google Scholar 

  • Neundörfer B, Heuß D (2006) Toxische Polyneuropathien. Thieme, Stuttgart, S 61–77

    Google Scholar 

  • Nicolini G, Monfrini M, Scuteri A (2015) Axonal transport impairment in chemotherapy-induced peripheral neuropathy. Toxics 3:322–341

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ocean AJ, Vahdat LT (2004) Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12:619–625

    PubMed  Google Scholar 

  • Park SB, Lin CS-Y, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC (2011) Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. Exp Neurol 227:120–127

    CAS  PubMed  Google Scholar 

  • Pasetto LM, D’Andrea MR, Rossi E, Monfardini S (2006) Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 59:159–168

    PubMed  Google Scholar 

  • Persohn E, Canta A, Schoepfer S (2005) Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 41:1460–1466

    CAS  PubMed  Google Scholar 

  • Pietrangeli A, Milella M, DeMarco S et al (2000) Brachial plexus neuropathy as unusual onset of diffuse neurolymphomatosis. Neurol Sci 21:241–245

    CAS  PubMed  Google Scholar 

  • Podratz JL, Knight AM, Ta LE (2011) Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis 41(3):661–668

    CAS  PubMed  Google Scholar 

  • Richardson PG, Xie W, Mitsiades C (2009) Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27:3518–3525

    CAS  PubMed  PubMed Central  Google Scholar 

  • Rolke R, Baron R, Maier C (2006) Quantitative sensory testing in the German research network on neuropathic pain (DFNS): standardized protocol and reference values. Pain 123(3):231–243

    CAS  PubMed  Google Scholar 

  • Schmincke C (2017) Ein Blick in die Anatomie des peripheren Nervensystems. In: Ratgeber Polyneuropathie und Restless Legs. Springer, Berlin/Heidelberg

    Google Scholar 

  • Shin SC, Robinson-Papp J (2012) Amyloid neuropathies. Mt Sinai J Med 79(6):733–748

    PubMed  PubMed Central  Google Scholar 

  • Steimann M (2014) Chemotherapieinduzierte Polyneuropathie: Grundlagen, Diagnostik und Prävention. GMS Onkol Rehabil Sozialmed 3:Doc05. https://doi.org/10.3205/ors000013. URN: urn:nbn:de:0183-ors0000139

    Article  Google Scholar 

  • Treede RD, Jensen TS, Campbell JN et al (2008) Neuropathic pain: redefinition and a grading system for clinical and research purposes Neurology. Neurology 70:1630–1635

    CAS  PubMed  Google Scholar 

  • Vass A, Grishold W (2009) Chemotherapie-induzierte Neuropathien (CIN). J Neurol Neurochir Psychi 10(2):44–47

    Google Scholar 

  • Verstappen CCP, Koeppen S, Heimans JJ et al (2005) Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64:1076–1077

    CAS  PubMed  Google Scholar 

  • Vliagoftis H, Befus AD (2005) Rapidly changing perspectives about mast cells at mucosal surfaces. Immunol Rev 206:190–203

    CAS  PubMed  Google Scholar 

  • Walsh LJ (2003) Mast cells and oral inflammation. Crit Rev Oral Biol Med 14(3):188–198

    PubMed  Google Scholar 

  • Wang MS, Wu Y, Culver DG, Glass JD (2000) Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy. J Neuropathol Exp Neurol 59:599–606

    CAS  PubMed  Google Scholar 

  • WHO (2001) . https://www.who.int/classifications/icf/en/. Zugegriffen am: 3.9.2019

  • Zedan AH, Vilholm OJ (2014) Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires. Basic Clin Pharmacol Toxicol 115(2):193–200

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik für Physikalische Medizin, Rehabilitation und Arbeitsmedizin, Medizinische Universität Wien, Wien, Österreich

    Mohammad Keilani & Richard Crevenna

  2. Universitätsklinik für Neurologie, Medizinische Universität Wien, Wien, Österreich

    Thomas Sycha

  3. Rehabilitationszentrum St. im Pongau Betriebs-GmbH, Onkologische Rehabilitation, St. Veit im Pongau, Österreich

    Thomas Licht

Authors
  1. Mohammad Keilani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Sycha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Licht
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard Crevenna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Keilani .

Editor information

Editors and Affiliations

  1. Universitätsklinik für Physikalische Medizin, Rehabilitation und Arbeitsmedizin, Medizinische Universität Wien, Wien, Austria

    Richard Crevenna

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Keilani, M., Sycha, T., Licht, T., Crevenna, R. (2020). Polyneuropathie bei Patienten mit onkologischen Erkrankungen. In: Crevenna, R. (eds) Onkologische Rehabilitation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57982-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-57982-4_8

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-57981-7

  • Online ISBN: 978-3-662-57982-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation